Protein-kinase inhibitors: A new treatment pathway for autoimmune and inflammatory diseases?

Although advances in biological medicine have seen significant progress in the treatment of autoimmune and inflammatory disease, many patients do not experience a satisfactory response. Hence, there are two challenges facing the medical research community. The first is to continue development in the field of existing biological therapies, such as monoclonal antibodies. The second is to open new frontiers of research and explore treatment alternatives for non-responders to other therapies. Attention has increasingly turned to the therapeutic potential of small molecule weight kinase inhibitors (SMKIs), currently used extensively in oncology and haematology. Initial research into the therapeutic value of SMKIs for autoimmune and inflammatory diseases has been encouraging. SMKIs are taken orally, which reduces cost for the health provider, and could increase compliance for the patient. This is why research is now focusing increasingly on SMKIs as a new generation line of treatment in these diseases. Tofacitinib, an inhibitor of Janus-kinase, is currently the only drug approved for the treatment of rheumatoid arthritis by FDA. However, much more needs to be done to understand the intracellular signalling pathways and how these might affect disease progression before solid conclusions can be drawn.

[1]  J. Cappelleri,et al.  Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes , 2015, BMC Gastroenterology.

[2]  J. Kremer,et al.  Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. , 2012, The New England journal of medicine.

[3]  D. Scott.  Role of Spleen Tyrosine Kinase Inhibitors in the Management of Rheumatoid Arthritis , 2011, Drugs.

[4]  K. Sada,et al.  Protein tyrosine kinase Syk in mast cell signaling. , 2002, Molecular immunology.

[5]  J. Blenis,et al.  ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions , 2004, Microbiology and Molecular Biology Reviews.

[6]  S. Chimenti,et al.  Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial , 2015, The Lancet.

[7]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[8]  S. Schreiber,et al.  Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  Gustavo Leon,et al.  Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study , 2014, Arthritis & rheumatology.

[10]  H. Patterson,et al.  Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases , 2014, Clinical and experimental immunology.

[11]  J. O’Shea,et al.  Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. , 2012, Current opinion in pharmacology.

[12]  A. Gottlieb,et al.  Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. , 2012, Journal of the American Academy of Dermatology.

[13]  G. Firestein,et al.  Anti-Inflammatory Effects and Joint Protection in Collagen-Induced Arthritis after Treatment with IQ-1S, a Selective c-Jun N-Terminal Kinase Inhibitor , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[14]  P. Rutgeerts,et al.  A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease , 2010, Gut.

[15]  Mark E Flanagan,et al.  Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. , 2014, Journal of medicinal chemistry.

[16]  Stanley B. Cohen,et al.  Kinase inhibitors: a new approach to rheumatoid arthritis treatment , 2010, Current opinion in rheumatology.

[17]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[18]  J. Mages,et al.  DUSP Meet Immunology: Dual Specificity MAPK Phosphatases in Control of the Inflammatory Response1 , 2006, The Journal of Immunology.

[19]  M. Bajpai,et al.  Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. , 2009, IDrugs : the investigational drugs journal.

[20]  E. Lee,et al.  Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies , 2014, The Journal of Rheumatology.

[21]  F. Salituro,et al.  VX-509 (Decernotinib) Is a Potent and Selective Janus Kinase 3 Inhibitor That Attenuates Inflammation in Animal Models of Autoimmune Disease , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[22]  J. Fridman,et al.  Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. , 2011, The Journal of investigative dermatology.

[23]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .

[24]  Douglas H. Thamm,et al.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.

[25]  H. Okamoto,et al.  Tyrosine kinases in rheumatoid arthritis , 2011, Journal of Inflammation.

[26]  M. Genovese,et al.  Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate , 2014, Annals of the rheumatic diseases.

[27]  A. Betz,et al.  The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[28]  D. Fruman,et al.  PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. , 2012, The Biochemical journal.

[29]  Juswinder Singh,et al.  Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[30]  L. Vargas,et al.  Inhibitors of BTK and ITK: State of the New Drugs for Cancer, Autoimmunity and Inflammatory Diseases , 2013, Scandinavian journal of immunology.

[31]  A. Doweyko,et al.  Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases. , 2010, Journal of medicinal chemistry.

[32]  D. Levy,et al.  JAK-STAT Signaling: From Interferons to Cytokines* , 2007, Journal of Biological Chemistry.

[33]  L. Audoly,et al.  Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis , 2008, Arthritis research & therapy.

[34]  M. Lodish.  Kinase Inhibitors: Adverse Effects Related to the Endocrine System , 2013 .

[35]  G. Firestein,et al.  Differential regulation of anti-inflammatory genes by p38 MAP kinase and MAP kinase kinase 6 , 2014, Journal of Inflammation.

[36]  Hiu Kiu,et al.  Biology and significance of the JAK/STAT signalling pathways , 2012, Growth factors.

[37]  Dean M. Messing,et al.  Anti-Inflammatory Properties of a Novel N-Phenyl Pyridinone Inhibitor of p38 Mitogen-Activated Protein Kinase: Preclinical-to-Clinical Translation , 2009, Journal of Pharmacology and Experimental Therapeutics.

[38]  Yoshiya Tanaka,et al.  Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. , 2014, Rheumatology.

[39]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[40]  Steven A. Bailey,et al.  JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. , 2012, Arthritis and rheumatism.

[41]  T. Cheng,et al.  Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[42]  A. Betz,et al.  Specific Inhibition of Spleen Tyrosine Kinase Suppresses Leukocyte Immune Function and Inflammation in Animal Models of Rheumatoid Arthritis , 2012, Journal of Pharmacology and Experimental Therapeutics.

[43]  S. Ward,et al.  Inhibition of PI3K Signaling Spurs New Therapeutic Opportunities in Inflammatory/Autoimmune Diseases and Hematological Malignancies , 2012, Pharmacological Reviews.

[44]  John J. O’Shea,et al.  Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550) , 2011, The Journal of Immunology.

[45]  C. Martínez-A,et al.  Tyr³²³-dependent p38 activation is associated with rheumatoid arthritis and correlates with disease activity. , 2011, Arthritis and rheumatism.

[46]  Charles Peterfy,et al.  An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. , 2011, Arthritis and rheumatism.

[47]  R. Fleischmann,et al.  A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis , 2015, Arthritis & rheumatology.

[48]  A. Šedivá,et al.  NF-κB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment , 2015, OncoTarget.

[49]  Christopher S. Stevenson,et al.  Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives. , 2013, Pharmacology & therapeutics.

[50]  H. Kung,et al.  Signaling network of the Btk family kinases , 2000, Oncogene.

[51]  K. Papp,et al.  A phase 2a randomized, double‐blind, placebo‐controlled, sequential dose‐escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate‐to‐severe psoriasis , 2015, The British journal of dermatology.

[52]  N. Damjanov,et al.  Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. , 2009, Arthritis and rheumatism.

[53]  D. Payan,et al.  An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. , 2008, Arthritis and rheumatism.

[54]  Tony Pawson,et al.  Profiling the kinome: current capabilities and future challenges. , 2013, Journal of proteomics.

[55]  J. Fridman,et al.  Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050 , 2010, The Journal of Immunology.

[56]  E. Martı́n-Mola,et al.  New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. , 2011, Rheumatology.

[57]  M. Gold,et al.  B-Cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-Cell Malignancies , 2013, International reviews of immunology.

[58]  Jonathan M Irish,et al.  Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. , 2008, Cancer cell.

[59]  Soohyun Kim,et al.  BIRB 796 has Distinctive Anti-inflammatory Effects on Different Cell Types , 2013, Immune network.

[60]  K. Reif,et al.  Antiarthritis Effect of a Novel Bruton's Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy , 2011, Journal of Pharmacology and Experimental Therapeutics.

[61]  E. Moilanen,et al.  Mitogen-activated protein kinase phosphatase 1 as an inflammatory factor and drug target. , 2014, Basic & clinical pharmacology & toxicology.

[62]  R. Plenge,et al.  JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. , 2012, Immunity.

[63]  Nathanael Gray,et al.  Factors underlying sensitivity of cancers to small-molecule kinase inhibitors , 2009, Nature Reviews Drug Discovery.

[64]  Mauro Riccaboni,et al.  Spleen tyrosine kinases: biology, therapeutic targets and drugs. , 2010, Drug discovery today.

[65]  T. Kodama,et al.  The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss. , 2014, Bone.

[66]  R. Rickert.  New insights into pre-BCR and BCR signalling with relevance to B cell malignancies , 2013, Nature Reviews Immunology.

[67]  Daigen Xu,et al.  Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase. , 2013, Arthritis and rheumatism.

[68]  Stanley B. Cohen,et al.  A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis , 2011, The Journal of Rheumatology.

[69]  G. Firestein,et al.  “Go upstream, young man”: lessons learned from the p38 saga , 2009, Annals of the rheumatic diseases.

[70]  K. Shuai,et al.  Regulation of cytokine signaling pathways by PIAS proteins , 2006, Cell Research.

[71]  Simon A. Jones,et al.  The problem of choice: current biologic agents and future prospects in RA , 2013, Nature Reviews Rheumatology.